Parkinson's Precision Markers Initiative

What Parkinson's Precision Markers Initiative does

Parkinson's Precision Medicine Initiative (PPMI) is a multi-site, international observational clinical study launched in 2010 to identify and validate biomarkers of Parkinson's disease progression. Sponsored and primarily funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), the study recruits participants with Parkinson's disease, prodromal individuals carrying genetic or clinical risk factors, and healthy controls through a network of nearly 50 international clinical sites. It operates as a non-profit research initiative rather than a commercial entity, distributing data and biospecimens at no cost to qualified investigators worldwide.

The platform's core technology is a longitudinal, multi-modal data repository combining clinical assessments, neuroimaging, 'omics, genetics, sensor streams, and biomarker measurements from 1,500+ participants followed since inception, with the cohort scaling toward 4,000+ volunteers. Delivered through interactive dashboards (Data Dashboard, Biomarkers Dashboard, Specimens Dashboard), an RNAseq portal hosted at the Laboratory of Neuro Imaging (LONI) at USC, and a biorepository of cell lines, CSF, plasma, serum, DNA, and RNA stored at Indiana University, the system is supplemented by over 20 sub-studies spanning PET imaging, digital health, genetics, and cognitive assessment. Partnerships with the New York Stem Cell Foundation and Cellular Dynamics International have produced iPSC and fibroblast lines, including gene-revertant controls.

PPMI's go-to-market is a community-led, open-access model: researchers apply through the MJFF grants portal, requests are reviewed by the Biospecimen Review Committee, and approved investigators receive data via LONI or biospecimens shipped from the Indiana University Biorepository. The study funds itself through MJFF sponsorship and other grants, has no commercial pricing for data access, and mandates open-access publication of resulting findings. The initiative is administered jointly by MJFF, LONI at USC, and Indiana University, with sub-study governance chaired by academic and industry scientific leaders.

Name

Parkinson's Precision Markers Initiative

Legal name

Parkinson's Precision Medicine Initiative

Website

https://ppmi-info.org

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

PPMI is an international observational clinical study launched in 2010 to validate Parkinson's disease biomarkers. Sponsored by The Michael J. Fox Foundation, it collects longitudinal multi-modal data from 4,000+ participants across nearly 50 sites and distributes open-access data and biospecimens to qualified researchers worldwide.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Population Genomics & Preventive Precision Health Programs (HLAAANAL)

Keywords

• Parkinson's biomarkers
• Clinical research data
• Biospecimen repository
• Longitudinal cohort study
• Neuroscience research

Headquarters

HQ city

Fullerton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Research Funding / Grant-based: PPMI is funded by The Michael J. Fox Foundation (MJFF) and other study sponsors. It is a non-profit research initiative, not a commercial entity generating revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

PPMI operates an open-access longitudinal clinical study and biospecimen library for Parkinson's disease research, enrolling 4,000+ volunteers (including 2,000 prodromal participants) across nearly 50 international clinical sites. The study collects and distributes clinical, imaging, 'omics, genetic, sensor, and biomarker data, along with standardized biospecimens (CSF, plasma, serum, DNA, RNA, PBMCs) and cell lines (fibroblasts, iPSCs with gene-revertant controls) to qualified researchers worldwide.

Product overview

The Parkinson's Precision Medicine Initiative (PPMI) is a landmark observational clinical study, not a traditional product company. PPMI operates a comprehensive research data platform comprising multiple integrated components: the PPMI Clinical Data Repository (containing clinical, imaging, 'omics, genetic, sensor, and biomarker data from 1,500+ participants at ~50 international sites), the Data Dashboard and Biomarkers Dashboard (interactive visualization tools), the Specimens Dashboard (inventory of biospecimens including CSF, Plasma, Serum, DNA, RNA), the RNAseq Data Portal, the Cell Lines Repository (fibroblasts and iPSCs from PD and control subjects), and Study Cohorts (categorized participant groups). The platform is supplemented by over 20 sub-studies spanning PET imaging, digital health, genetic analysis, and cognitive assessments. All data is open-access to qualified researchers. The study began enrollment in 2010 and is expanding to over 4,000 volunteers including 2,000 prodromal participants.

Differentiator

Problem solved

Functional benefit

Products and services

• PPMI Clinical Data Repository
• PPMI Biospecimen Collection
• PPMI Cell Lines Repository Collection of fibroblasts and induced pluripotent stem cell (iPSC) lines derived from PPMI participants, including matched lines from 20 Parkinson's disease subjects and 5 healthy controls, plus PBMC-derived iPSCs across GBA, LRRK2, SNCA, and sporadic PD cohorts. Includes gene-revertant controls with mutations edited back to wild type, deposited back in the biorepository for community research access.
• PPMI Sub-Studies Add-on research studies aligned with PPMI's scientific goals spanning imaging modalities (Early Imaging, Tau PET, AV-133, SV2A PET, DPA-714 PET, C05-05 PET), digital health (Gait, Digital), genetic analysis (LRRK2 LITE), and cognitive assessments (Cognitive Activities, Mapping Symptoms). Provides targeted specialized research capabilities for Parkinson's disease investigators.

Quantifiable outcome

• Open-access publications policy ensures research findings are freely available to the scientific community
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• New York Stem Cell FoundationcoreStrategic or Co-development PartnerPartnership produced fibroblasts and iPSCs derived from skin biopsies from 20 PD subjects and 5 control subjects. Generated gene-revertant controls with mutations edited back to wild type deposited back in the biorepository for community access.
• Cellular Dynamics InternationalcoreStrategic or Co-development PartnerPartnership supported by Golub Capital generated iPSCs from blood from subjects across cohorts, expanding the available cell line inventory for researchers.
• Laboratory of Neuro Imaging (LONI) at USCcoreTechnology or IntegrationManages the PPMI data repository, data access portal, and provides data unblinding services for researchers who submit specimen analysis results.
• Indiana UniversitycoreStrategic or Co-development PartnerBiorepository Core at Indiana University stores and ships biospecimens including cell lines, CSF, plasma, serum, and other samples to approved researchers.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• All of Us Research Program: NIH's All of Us Research Program is a major US precision medicine initiative enrolling 1 million+ participants to collect clinical, genetic, and digital health data for open-access research. Like PPMI, it is a longitudinal observational study with multi-modal data and biospecimen sharing for disease research.
• Fox Insight: Fox Insight is MJFF's online longitudinal study for Parkinson's disease, also collecting self-reported data and digital health information. While PPMI focuses on in-clinic deep phenotyping, Fox Insight enables massive-scale participation - together they form a complementary research platform under the same parent sponsor.
• BioFIND: BioFIND is MJFF's earlier Parkinson's disease biomarker discovery study collecting clinical data and biospecimens from PD patients and controls. It is a predecessor/companion study to PPMI under the same MJFF umbrella, focused on biomarker discovery for PD.
• UK Biobank: UK Biobank is the largest population-scale prospective biobank with 500,000+ participants, providing access to genetic, imaging, and health record data. Like PPMI, it operates as an open-access research resource with longitudinal data and biospecimen infrastructure for academic and industry researchers.
• Parkinson's Progression Markers Initiative (PPMI) - similar consortium models: Note: PPMI itself is the subject. Comparable prior cohort programs include the Parkinson's Disease Biomarkers Program (PDBP) from NINDS, which similarly collected longitudinal biospecimens and clinical data from PD patients for biomarker discovery.
• Cure Parkinson's Trust (CurePD): Cure Parkinson's (formerly Cure Parkinson's Trust) is a UK-based research-driven charity funding clinical trials and biomarker initiatives for PD. While focused on trials rather than observational research, it shares PPMI's mission of accelerating PD therapeutic development through structured research infrastructure.
• Global Parkinson's Genetics Program (GP2): GP2 is an ambitious global genotyping effort specifically targeting Parkinson's disease genetics in under-represented populations. It complements PPMI by addressing genetic diversity gaps and is led by the Aligning Science Across Parkinson's initiative, with similar open-access research models.
• Alzheimer's Disease Neuroimaging Initiative (ADNI): ADNI is the direct structural analog of PPMI for Alzheimer's disease - a longitudinal observational study collecting clinical, imaging, biomarker, and genetic data, sharing data openly through LONI. Both studies pioneered the disease-specific open-access biomarker model that PPMI has applied to Parkinson's.

Others

• Laboratory of Neuro Imaging (LONI) at USC: LONI is the technology partner that manages the PPMI data repository and access portal. LONI also hosts ADNI, providing the data infrastructure backbone for multiple disease-specific research initiatives comparable to PPMI's data infrastructure approach.

Broad incumbents

• Michael J. Fox Foundation for Parkinson's Research (MJFF): MJFF is PPMI's primary sponsor and parent organization, and the largest private funder of Parkinson's disease research globally. While MJFF is a foundation running multiple research programs (Fox Insight, BioFIND, PPMI), it is the institutional context within which PPMI operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parkinson's Precision Markers Initiative